SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-24-000062
Filing Date
2024-05-09
Accepted
2024-05-09 07:14:33
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20240509.htm   iXBRL 8-K 28426
2 EX-99.1 exh991q12024earningsrelease.htm EX-99.1 85682
6 picture1revised.jpg GRAPHIC 4446
  Complete submission text file 0001867096-24-000062.txt   257700

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20240509.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20240509_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20240509_pre.xml EX-101.PRE 13046
18 EXTRACTED XBRL INSTANCE DOCUMENT xers-20240509_htm.xml XML 2833
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 24928544
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)